Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever

By LabMedica International staff writers
Posted on 04 Aug 2026

Lassa fever remains a persistent public health threat in West Africa, causing an estimated 100,000–300,000 infections annually and high case fatality rates among hospitalized patients. More...

Clinical management is hampered by delays when samples must be transported to distant laboratories under challenging logistics. Faster, site-based diagnosis is critical for both patient care and outbreak control. 

Alveo Technologies and The University of Texas Medical Branch (UTMB) have formed a partnership to develop point-of-care diagnostics for viral hemorrhagic fevers, with an initial focus on Lassa fever. The collaboration supports UTMB’s Lassa fever research program and is intended to provide immediate testing capability at participating clinical sites. The effort is structured within an open-platform partner model that also enables academic teams to build assays for priority pathogens.

The diagnostic approach centers on a portable, cloud-connected molecular platform designed to deliver laboratory-quality detection at the point of need. Real-time analysis is performed on site, and results are transmitted through an accompanying application to support rapid decision-making. The platform is being validated to maintain performance across variable operator experience, environmental conditions, and individual analyzer units.

Before deployment to diverse field settings, the system is undergoing high-containment evaluation at UTMB’s Galveston National Laboratory under biosafety level 4 (BSL-4) conditions. In related work that demonstrates environmental robustness, the platform was field tested in Peru for avian influenza surveillance, where teams assessed operation in warm, humid, and dusty environments. All testing materials were transported in a small bag, and results were returned on site in real time via the application interface. The collaboration is part of a broader partner program that connects research institutions and industry to accelerate assay development for settings with significant unmet public health needs. Operations at the Galveston National Laboratory were supported by National Institutes of Health grant UC7AI094660 for BSL-4 operations.

“There is a clear and immediate need for a reliable point-of-care diagnostic for Lassa fever. Having immediate diagnostic capabilities at our field sites will fundamentally change how we respond to Lassa fever cases in affected communities,” said Dr. Courtney Woolsey, Professor in UTMB's Department of Microbiology & Immunology and Principal Investigator of the Lassa fever research program.

“UTMB is helping us to further push the capabilities of molecular testing to support critical research and outbreak response in the world's most remote locations. Beyond the development of a diagnostic for Lassa Fever, UTMB faculty are engaged in validating and deploying our technology in exactly the types of real-world applications our technology was designed for,” said Shaun Holt, CEO of Alveo Technologies.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.